A Targeted and pH-Responsive Nano-Graphene Oxide Nanoparticle Loaded with Doxorubicin for Synergetic Chemo-Photothermal Therapy of Oral Squamous Cell Carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Huang SH, O’Sullivan B. Oral cancer: current role of radiotherapy and chemotherapy. Med Oral Patol Oral Cir Bucal. 2013;18(2):e233–e240. doi:10.4317/medoral.18772
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.387
   PubMed Web of Science ®Google Scholar
• Cao M, Shi E, Wang H, et al. Personalized targeted therapeutic strategies against oral squamous cell carcinoma. an evidence-based review of literature. Int J Nanomedicine. 2022;17:4293–4306. doi:10.2147/IJN.S377816
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang M, Cheng M, et al. Tumor microenvironment in head and neck squamous cell carcinoma: functions and regulatory mechanisms. Cancer Lett. 2021;507:55–69. doi:10.1016/j.canlet.2021.03.009
   PubMed Web of Science ®Google Scholar
• Gu F, Hu C, Cao W, et al. Tumor microenvironment multiple responsive nanoparticles for targeted delivery of doxorubicin and CpG against triple-negative breast cancer. Int J Nanomedicine. 2022;17:4401–4417. doi:10.2147/IJN.S377702
   PubMed Web of Science ®Google Scholar
• Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–598. doi:10.1038/nrc.2016.73
   PubMed Web of Science ®Google Scholar
• Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257–266. doi:10.1158/1535-7163.Mct-11-0340
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen J, Pang Y, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12(4):1557–1569. doi:10.7150/thno.69475
   PubMed Web of Science ®Google Scholar
• Feng X, Wang Q, Liao Y, et al. A synthetic urinary probe-coated nanoparticles sensitive to fibroblast activation protein alpha for solid tumor diagnosis. Int J Nanomedicine. 2017;12:5359–5372. doi:10.2147/IJN.S139039
   PubMed Web of Science ®Google Scholar
• Chen WH, Lecaros RL, Tseng YC, et al. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett. 2015;359(1):65–74. doi:10.1016/j.canlet.2014.12.052
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776
   PubMed Web of Science ®Google Scholar
• Fan W, Yung B, Huang P, et al. Nanotechnology for multimodal synergistic cancer therapy. Chem Rev. 2017;117(22):13566–13638. doi:10.1021/acs.chemrev.7b00258
   PubMed Web of Science ®Google Scholar
• Yan F, Duan W, Li Y, et al. NIR-laser-controlled drug release from DOX/IR-780-loaded temperature-sensitive-liposomes for chemo-photothermal synergistic tumor therapy. Theranostics. 2016;6(13):2337–2351. doi:10.7150/thno.14937
   PubMed Web of Science ®Google Scholar
• Li Y, Nie J, Dai J, et al. pH/redox dual-responsive drug delivery system with on-demand RGD exposure for photochemotherapy of tumors. Int J Nanomedicine. 2022;17:5621–5639. doi:10.2147/IJN.S388342
   PubMed Web of Science ®Google Scholar
• Olejniczak J, Carling CJ, Almutairi A. Photocontrolled release using one-photon absorption of visible or NIR light. J Control Release. 2015;219:18–30. doi:10.1016/j.jconrel.2015.09.030
   PubMed Web of Science ®Google Scholar
• Melamed JR, Edelstein RS, Day ES. Elucidating the fundamental mechanisms of cell death triggered by photothermal therapy. ACS Nano. 2015;9(1):6–11. doi:10.1021/acsnano.5b00021
   PubMed Web of Science ®Google Scholar
• Zou L, Wang H, He B, et al. Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics. 2016;6(6):762–772. doi:10.7150/thno.14988
   PubMed Web of Science ®Google Scholar
• Navarro-Palomares E, Garcia-Hevia L, Galan-Vidal J, et al. Shiga toxin-B targeted gold nanorods for local photothermal treatment in oral cancer clinical samples. Int J Nanomedicine. 2022;17:5747–5760. doi:10.2147/IJN.S381628
   PubMed Web of Science ®Google Scholar
• Zhou F, Wang M, Luo T, et al. Photo-activated chemo-immunotherapy for metastatic cancer using a synergistic graphene nanosystem. Biomaterials. 2021;265:120421. doi:10.1016/j.biomaterials.2020.120421
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhou X, Xing D. Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier. Biomaterials. 2014;35(13):4185–4194. doi:10.1016/j.biomaterials.2014.01.044
   PubMed Web of Science ®Google Scholar
• Liu J, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 2013;9(12):9243–9257. doi:10.1016/j.actbio.2013.08.016
   PubMed Web of Science ®Google Scholar
• Sattari S, Adeli M, Beyranvand S, et al. Functionalized graphene platforms for anticancer drug delivery. Int J Nanomedicine. 2021;16:5955–5980. doi:10.2147/IJN.S249712
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Han JW, Park JH, et al. Reduced graphene oxide-silver nanoparticle nanocomposite: a potential anticancer nanotherapy. Int J Nanomedicine. 2015;10:6257–6276. doi:10.2147/IJN.S92449
   PubMed Web of Science ®Google Scholar
• Peng C, Hu W, Zhou Y, et al. Intracellular imaging with a graphene-based fluorescent probe. Small. 2010;6(15):1686–1692. doi:10.1002/smll.201000560
   PubMed Web of Science ®Google Scholar
• Yang K, Feng L, Shi X, et al. Nano-graphene in biomedicine: theranostic applications. Chem Soc Rev. 2013;42(2):530–547. doi:10.1039/c2cs35342c
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Kim JH. Synthesis, toxicity, biocompatibility, and biomedical applications of graphene and graphene-related materials. Int J Nanomedicine. 2016;11:1927–1945. doi:10.2147/IJN.S105264
   PubMed Web of Science ®Google Scholar
• Kiew SF, Kiew LV, Lee HB, et al. Assessing biocompatibility of graphene oxide-based nanocarriers: a review. J Control Release. 2016;226:217–228. doi:10.1016/j.jconrel.2016.02.015
   PubMed Web of Science ®Google Scholar
• Liu Z, Robinson JT, Sun X, et al. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc. 2008;130(33):10876–10877. doi:10.1021/ja803688x
   PubMed Web of Science ®Google Scholar
• Yang HW, Lu YJ, Lin KJ, et al. EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy. Biomaterials. 2013;34(29):7204–7214. doi:10.1016/j.biomaterials.2013.06.007
   PubMed Web of Science ®Google Scholar
• Thapa RK, Byeon JH, Ku SK, et al. Easy on-demand self-assembly of lateral nanodimensional hybrid graphene oxide flakes for near-infrared-induced chemothermal therapy. NPG Asia Mater. 2017;9(8):e416–e416. doi:10.1038/am.2017.141
   Google Scholar
• Egorin MJ, Hildebrand RC, Cimino EF, et al. Cytofluorescence localization of Adriamycin and daunorubicin. Cancer Res. 1974;34(9):2243–2245.
   PubMed Web of Science ®Google Scholar
• Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;11(24 Pt 1):8782–8788. doi:10.1158/1078-0432.Ccr-05-1664
   PubMed Web of Science ®Google Scholar
• Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. West J Med. 1979;131(5):364–368.
   PubMedGoogle Scholar
• Rong P, Yang K, Srivastan A, et al. Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics. 2014;4(3):229–239. doi:10.7150/thno.8070
   PubMed Web of Science ®Google Scholar
• Tian B, Wang C, Zhang S, et al. Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano. 2011;5(9):7000–7009. doi:10.1021/nn201560b
   PubMed Web of Science ®Google Scholar
• Eda G, Chhowalla M. Chemically derived graphene oxide: towards large-area thin-film electronics and optoelectronics. Adv Mater. 2010;22(22):2392–2415. doi:10.1002/adma.200903689
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Q, Chu X, et al. Graphene oxide-peptide conjugate as an intracellular protease sensor for caspase-3 activation imaging in live cells. Angew Chem Int Ed Engl. 2011;50(31):7065–7069. doi:10.1002/anie.201101351
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu K, Luo Z, et al. Preparation and tumor cell model based biobehavioral evaluation of the nanocarrier system using partially reduced graphene oxide functionalized by surfactant. Int J Nanomedicine. 2015;10:4605–4620. doi:10.2147/ijn.S82354
   PubMed Web of Science ®Google Scholar
• Madhusudhan A, Reddy GB, Venkatesham M, et al. Efficient pH dependent drug delivery to target cancer cells by gold nanoparticles capped with carboxymethyl chitosan. Int J Mol Sci. 2014;15(5):8216–8234. doi:10.3390/ijms15058216
   PubMed Web of Science ®Google Scholar
• Zhang Y, Song T, Feng T, et al. Plasmonic modulation of gold nanotheranostics for targeted NIR-II photothermal-augmented immunotherapy. Nano Today. 2020;35:100987. doi:10.1016/j.nantod.2020.100987
   Web of Science ®Google Scholar
• Quader S, Liu X, Toh K, et al. Supramolecularly enabled pH- triggered drug action at tumor microenvironment potentiates nanomedicine efficacy against glioblastoma. Biomaterials. 2021;267:120463. doi:10.1016/j.biomaterials.2020.120463
   PubMed Web of Science ®Google Scholar
• Wang Y, Li L, Li J, et al. Stable and pH-responsive polyamidoamine based unimolecular micelles capped with a zwitterionic polymer shell for anticancer drug delivery. RSC Adv. 2016;6(21):17728–17739. doi:10.1039/c5ra25505h
   Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–1170. doi:10.1038/nbt1340
   PubMed Web of Science ®Google Scholar
• Gharat SA, Momin M, Bhavsar C. Oral squamous cell carcinoma: current treatment strategies and nanotechnology-based approaches for prevention and therapy. Crit Rev Ther Drug Carrier Syst. 2016;33(4):363–400. doi:10.1615/CritRevTherDrugCarrierSyst.2016016272
   PubMed Web of Science ®Google Scholar
• Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8(9):11884–11894.
   PubMed Web of Science ®Google Scholar
• Hammann F, Gotta V, Conen K, et al. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol. 2017;83(4):927–930. doi:10.1111/bcp.13155
   PubMed Web of Science ®Google Scholar
• Lungu II, Grumezescu AM, Volceanov A, et al. Nanobiomaterials used in cancer therapy: an up-to-date overview. Molecules. 2019;24(19):3547. doi:10.3390/molecules24193547
   PubMed Web of Science ®Google Scholar
• Teleanu DM, Chircov C, Grumezescu AM, et al. Contrast agents delivery: an up-to-date review of nanodiagnostics in neuroimaging. Nanomaterials. 2019;9(4):542. doi:10.3390/nano9040542
   Web of Science ®Google Scholar
• Hoseini-Ghahfarokhi M, Mirkiani S, Mozaffari N, et al. Applications of graphene and graphene oxide in smart drug/gene delivery: is the world still flat? Int J Nanomedicine. 2020;15:9469–9496. doi:10.2147/IJN.S265876
   PubMed Web of Science ®Google Scholar
• Yang K, Zhang S, Zhang G, et al. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010;10(9):3318–3323. doi:10.1021/nl100996u
   PubMed Web of Science ®Google Scholar
• Mirrahimi M, Alamzadeh Z, Beik J, et al. A 2D nanotheranostic platform based on graphene oxide and phase-change materials for bimodal CT/MR imaging, NIR-activated drug release, and synergistic thermo-chemotherapy. Nanotheranostics. 2022;6(4):350–364. doi:10.7150/ntno.64790
   PubMedGoogle Scholar
• Zhang X, Luo L, Li L, et al. Trimodal synergistic antitumor drug delivery system based on graphene oxide. Nanomedicine. 2019;15(1):142–152. doi:10.1016/j.nano.2018.09.008
   PubMed Web of Science ®Google Scholar
• Li R, Gao R, Zhao Y, et al. pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy. Front Oncol. 2022;12:930920. doi:10.3389/fonc.2022.930920
   PubMed Web of Science ®Google Scholar
• Robinson JT, Tabakman SM, Liang Y, et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc. 2011;133(17):6825–6831. doi:10.1021/ja2010175
   PubMed Web of Science ®Google Scholar
• Sun X, Liu Z, Welsher K, et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res. 2008;1(3):203–212. doi:10.1007/s12274-008-8021-8
   PubMed Web of Science ®Google Scholar
• Wang H, Wu Q, Liu Z, et al. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 2014;5(4):e1155. doi:10.1038/cddis.2014.122
   PubMed Web of Science ®Google Scholar
• Huang S, Fang R, Xu J, et al. Evaluation of the tumor targeting of a FAPalpha-based doxorubicin prodrug. J Drug Target. 2011;19(7):487–496. doi:10.3109/1061186X.2010.511225
   PubMed Web of Science ®Google Scholar
• Wang Y, Jing Y, Ding L, et al. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway. J Exp Clin Cancer Res. 2019;38(1):274. doi:10.1186/s13046-019-1277-x
   PubMedGoogle Scholar
• Wu QQ, Zhao M, Huang GZ, et al. Fibroblast Activation Protein (FAP) overexpression induces Epithelial-Mesenchymal Transition (EMT) in oral squamous cell carcinoma by Down-Regulating Dipeptidyl Peptidase 9 (DPP9). Onco Targets Ther. 2020;13:2599–2611. doi:10.2147/ott.S243417
   PubMed Web of Science ®Google Scholar
• Nijkamp MM, Span PN, Hoogsteen IJ, et al. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol. 2011;99(3):344–348. doi:10.1016/j.radonc.2011.05.066
   PubMed Web of Science ®Google Scholar
• Bughda R, Dimou P, D’Souza RR, et al. Fibroblast activation protein (FAP)-Targeted CAR-T cells: launching an attack on tumor stroma. Immunotargets Ther. 2021;10:313–323. doi:10.2147/itt.S291767
   PubMed Web of Science ®Google Scholar
• Shi Y, van der Meel R, Chen X, et al. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921–7924. doi:10.7150/thno.49577
   PubMed Web of Science ®Google Scholar
• Wang H, Zhou J, Fu Y, et al. Deeply infiltrating iRGD-graphene oxide for the intensive treatment of metastatic tumors through PTT-mediated chemosensitization and strengthened integrin targeting-based antimigration. Adv Healthc Mater. 2021;10(16):e2100536. doi:10.1002/adhm.202100536
   PubMed Web of Science ®Google Scholar
• Bardajee GR, Hooshyar Z, Farsi M, et al. Synthesis of a novel thermo/pH sensitive nanogel based on salep modified graphene oxide for drug release. Mater Sci Eng C Mater Biol Appl. 2017;72:558–565. doi:10.1016/j.msec.2016.11.109
   PubMed Web of Science ®Google Scholar